A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) versus Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy.(MMY3008)
A Phase 3, Double-Blind, Placebo-Controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia AC220-A-U302.
A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS WHO REQUIRE RED BLOOD CELL TRANSFUSIONS. )
A RANDOMIZED, DOUBLE BLIND PHASE 1B/2 STUDY OF PF 04449913 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED INTERMEDIATE 2 OR HIGH RISK MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA WITH 20 30% BLASTS AND MULTI LINEAGE DYSPLASIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA.
BMS CA180-543 (TRAD)
The study population will consist of patients who have Chronic Myeloid Leukemia with a molecular response of 4.5 confirmed twice as stable during screening while on Imatinib. (TRAD - Treatment-free Remission Accomplished with Dasatinib in Patients with CML). (Ozmosis Study No. OZM-056)
A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patient with Relapsed or Refractory System Light Chain (AL) Amyloidosis.
A Phase III, Randomized, Double-Blind Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagnosed Multiple Myeloma.
CC-4047-MM003/ Companion Study
Open-Label. Multi-Center, Sigle-Arm Study for the Safety and Efficacy of Pomalidomide (CC-4047) Monotheraphy for subjects with Refractory or Relapsed and Refractory Multiple Myeloma. A Companion Study for Clinical Trial CC-4047-MM003.
A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA FOLLOWING LENALIDOMIDE PLUS DEXAMETHASONE IN THE SECOND-LINE SETTING.
Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects with Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma. (ROBUST)
A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients with Advanced Hematological Malignancies. (Ozmosis Study No. OZM-040)
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma.
MULTI-STAGE RANDOMIZED PHASE II STUDY OF NOVEL COMBINATION THERAPY IN THE TREATMENT OF RELAPSED AND REFRACTORY AGGRESSIVE B-CELL LYMPHOMA. (NCIC CTG)
Participation of a National Myelodysplastic Syndrome (MDS) Database.
A Phase 1b Multicenter, Open-label Study to Determine the Recommended Dose and Regimen of Durvalumab (MEDI4736) Either as Monotherapy or in Combination With Pomalidomide (POM) With or Without Low Dose-Dexamethasone (dex) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM). (MEDi4736)
A Phase 1/2, multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subjects with newly diagnosed multiple myeloma (NDMM).
A Phase III study of Pomalidomide and low dose Dexamethasone with or without embrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM).
(KEYNOTE 183) IND NUMBER: 118604; EudraCT NUMBER: 2015-002509-13
A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles.
A non-interventional study exploring quality of life in multiple myeloma according to treatment following autologous stem cell transplant.
An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 versus Chlorambucil).
PHL-091 (NCI 9460)
A Phase 2 Study of Sequential Trametinib and GSK2141795 in Relapsed or Refractory Multiple Myeloma.
S1203 (NCIC ALC.3)
A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML).
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents
A PHASE IB/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE
THE EFFICACY AND SAFETY OF VISMODEGIB IN COMBINATION WITH RUXOLITINIB VERSUS
PLACEBO AND RUXOLITINIB IN PATIENTS WITH INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS.
2215 -301 Admiral
A phase 3 open-label multicenter randomized study of ASP2215 vs salvage chemotherpay in pts with relapsed or refractory AML with FLT3 mutation.Conducted at the University of Alberta Hospital.
Phase II randomized study of Rigosertib vs Physician's choice in MDS after failure of hypomethylatinbg agent.Conducted at the University of Alberta Hospital.
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy
A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
AC220-A -U302 Quantum First
A Phase 3, Double Blind, Placebo controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM-First).Conducted at the University of Alberta Hospital.
A Phase 1b/2 Multicenter, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed-and-Refractory Multiple Myeloma
AG221 - AML-004
A Phase 3, Multicenter, Open-label, Randomized Study comparing the efficacy and safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation.Conducted at the University of Alberta Hospital.
Astex SGI 110-07
A Phase 3, Multicenter, Randomized, Open-label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents.Conducted at the University of Alberta Hospital.
A Phase 3 Randomized, Double-blind Study of Oral Azacitidine vs Placebo in Subjects with RBC Transfusion-dep. Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.Conducted at the University of Alberta Hospital.
An Open-Label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have previously participated in Bosutinib Studies B1871006 or B1871008
Millenium C16011 A Phase 3 Randomized, Controlled, Open-Label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 Or Physician’s Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
CA 209 602
An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents.Conducted at the University of Alberta Hospital.
A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone inpatients with relapsed or relapsed/refractory multiple myeloma who have been previously exposed to immunomodulatory agents
A PHASE IB/II MULTI-ARM STUDY WITH VENETOCLAX IN COMBINATION WITH COBIMETINIB AND VENETOCLAX IN COMBINATION WITH IDASANUTLIN IN PATIENTS AGED ≥60 YEARS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WHO ARE NOT ELIGIBLE FOR CYTOTOXIC THERAPY.Conducted at the University of Alberta Hospital.
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DCDT2980S in Combination with Rituximab or DCDS4501A in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
A Phase Ib/II, open-label study evaluating the safety and pharmacokinetics Of GDC-0199 (ABT-199) in combination with Rituximab (r) or Obinutuzumab (g) plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (chop) in patients With b-cell Non-Hodgkin’s lymphoma (NHL) and DLBCL
Dose Optimization Study of Idelalisib in Follicular Lymphoma
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for
Resistant/Refractory Multiple Myeloma
A Phase II Study of Using a Combination of Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients who have Received Bortezomib-based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance until Disease Progression
A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT).Conducted at the University of Alberta Hospital.
A Phase 1/2 multicenter, open-label study to determine the recommended dose and regimen of durvalumab (medi4736) in Combination with lenalidomide (len) with and without
Dexamethasone (dex) in subjects with newly diagnosed\ multiple myeloma (ndmm)
Phase 2 Study of Sequential Trametinib and GSK2141795 in Relapsed or Refractory Multiple Myeloma
A phase II study of Buparlisib in patients with relapsed and refractory chronic lymphocytic leukemia
A single arm phase II study of high-dose weekly Carfilzomib plus cyclophosphamide and dexamethasone in The treatment of relapsed multiple myeloma after 1-3 Prior therapies
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis
A Randomized, Double-Blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in Subjects with Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms,Conducted at the University of Alberta Hospital.
TRAD - OZM-056
Treatment-free Remission Accomplished with Dasatinib
in Patients with CML.Conducted at the University of Alberta Hospital.